CN1508265A - Interleukin-2 and tes method of its gene in drug-stopping application - Google Patents
Interleukin-2 and tes method of its gene in drug-stopping application Download PDFInfo
- Publication number
- CN1508265A CN1508265A CNA021550581A CN02155058A CN1508265A CN 1508265 A CN1508265 A CN 1508265A CN A021550581 A CNA021550581 A CN A021550581A CN 02155058 A CN02155058 A CN 02155058A CN 1508265 A CN1508265 A CN 1508265A
- Authority
- CN
- China
- Prior art keywords
- mouse
- morphine
- injection
- group
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses an interleukin-2 (IL-2) and testing method of its gene in application to stopping drug taking. It shows that to inject IL-2 protein in the under cavity of cobweb film has better effect of stopping drug taking, the effect showing dosage dependency. The pcDNA3-IL-2 gene has also a certain effect of stopping drug taking, and if the lead-in condition is further optimized, the effect can be better and more practical.
Description
Technical field:
The invention belongs to gene engineering technology field.Be specifically related to interleukin II (IL-2) and gene thereof the testing method in drug rehabilitation is used.
Background technology:
Drugs, not only serious harm human health, whole world drug addict has the many populations of 1 second, has brought a series of insoluble problems to society.To the able-bodied drugs of harm world people, national governments and scientists are just sparing no effort to study, develop to remove medicine and the method that drugs produce physiology/psychoreaction, make the drug addict reach the purpose of detoxification, de-addiction rapidly.But because special physiology and psychoreaction that drugs cause, fail so far to find a kind of drug addict's of making safety, effectively, no dependence ground breaks away from " miraculous cure " of drugs.Prior treatment method exists the side effect that is difficult to accept, and its application is also usually because habituation and limited.And whole work to the pharmacological dependence Journal of Sex Research still rests in the vicious circle of " new morphine compounds replaces old morphine compounds ", and " methadone successive subtraction method ", still used as " standard care " so far by developed country.Society presses for a kind of no habituation own, better control Withrawal symptom and the little medicine of toxic side effect is arranged.
The discovery of the analgesic activity of a kind of important lymphokine-interleukin II in the immunity system and the effect of control morphine abstinence syndrome symptom may provide an important instrument for us.China Liu Xin wall academician etc. finds that at first IL-2 has analgesic activity.Experiment shows that the existing central analgesia effect of IL-2 has the periphery analgesic activity again, and the clinical observation discovery has good analgesic effect after the not good terminal cancer pain patient of analgesic effect is used IL-2.Experiment finds that also the analgesic activity of IL-2 may be relevant with opiate receptor.Reach morphine on insensitive europathology pain model in the morphine tolerance, IL-2 has more significant analgesic activity than morphine.Because drug addict's immunologic hypofunction, IL-2 are expected to improve on the one hand body's immunological function, control Withrawal symptom on the one hand.Yet IL-2 active transformation period in body is very short, must heavy dose of continuous use, and the trouble of medical expenses height and long term injections, thus influenced the widespread use of result of treatment and this medicine.Gene therapy is to address this problem to have brought new hope, and it is a kind of method by transgenosis, will have the carrier of expressing goal gene and import in relevant cell and the tissue, makes the method for transcribing with translation product performance therapeutic action.The genophore that is used for gene therapy at present has virus vector and non-virus carrier.Liposome belongs to the latter, and the transgenosis safe of its mediation is good, is used in body (in vivo) gene therapy; The virus vector good stability, transgene efficiency height, but transfection division or somatoblast not; After adenovirus enters nucleus, form with episome (episome) exists, and does not integrate, and does not therefore have carcinogenic, the mutagenicity of retroviral vector potential, security is better, and it is neural in the body gene therapy that these characteristics have determined that adenovirus is very suitable for.After adenovirus carrier injects subarachnoid space, adenovirus enters pia mater spinalis and arachnoid membrane internal breeding, gene expression product acts on spinal cord and sensory nerve root with " paracrine pattern ", can regulate and control nerve in spinal levels, this gene therapy mode is worn and can be finished by waist, so be hopeful to be applied to out-patient's treatment.
Summary of the invention:
Technical problem to be solved by this invention is to design the testing method of IL-2 gene in drug rehabilitation is used, thereby can adopt IL-2 albumen, pcDNA3 plasmid-lipidosome or adenovirus vector-mediated IL-2 transgenosis to subarachnoid space, reach control morphine abstinence syndrome symptom, make the drug rehabilitation function of IL-2 reach the purpose of clinical application.
The invention provides a kind of interleukin II and gene thereof the testing method in drug rehabilitation is used, this method comprises the following steps:
(1) structure of eukaryon expression plasmid pcDNA3-IL-2
Human IL-2's gene is cut the human IL-2 cDNA (462bp) that the total length that obtains EcoR I and Xho I joint contains signal peptide through EcoR I and Xho I enzyme and is cloned into the pcDNA3 carrier of cutting through same enzyme (Invitrogen).The IL-2 gene is expressed under the control of CMV promotor, and the plasmid of structure is transformed into the e. coli jm109 amplification, and alkaline lysis prepares plasmid, the polyethylene glycol precipitation purifying.Determine plasmid concentration by the photoabsorption of measuring 260nm, plasmid is diluted in the phosphoric acid buffer (PB) that contains 5% glucose during injection;
(2) structure of recombinant adenovirus Ad5-IL-2
Human IL-2's gene is cut the human IL-2 cDNA (462bp) that the total length that obtains EcoR I and Xho I joint contains signal peptide through EcoR I and Xho I enzyme and is cloned into the pCA13 carrier of cutting through same enzyme (Microbix).Obtain pCA13-IL-2, this moment, the IL-2 gene was expressed under the control of CMV promotor, pCA13-IL-2 and adenoviral gene group plasmid pBHG10 (Microbix) cotransfection 293 cells, carry out homologous recombination, the screening recombinant adenovirus, the amplification purification adenovirus, viral dilution is in the PBS that contains 5% sucrose during injection;
(3) morphine relies on the foundation of (habituation) mouse model
Form morphine-dependent mice model (this group mouse is a morphine dependence group) with incremental dose method.Morphine-dependent mice abdominal injection naloxone 4mg.kg
-1Can excite Withrawal symptom, this group mouse is the morphine abstinence syndrome group;
(4) morphine relies on the foundation of rat model
Form morphine with incremental dose method and rely on rat model (this group rat is a morphine dependence group).Morphine relies on rats by intraperitoneal injection naloxone 4mg.kg
-1Can excite Withrawal symptom, this group rat is the morphine abstinence syndrome group;
(5) foundation of the plasmid-mediated IL-2 gene inhibition of IL-2 albumen and pcDNA3 mouse morphine abstinence syndrome symptom testing method
With the morphine addiction mouse model that incremental dose method is set up, after 3 hours the mouse of habituation is divided into 8 groups at random, 10 every group for morphine at last.The protein for treatment group: (subarachnoid space) injects 5 * 10 respectively between the 5th and the 6th lumbar vertebrae
3, 1 * 10
4, 2 * 10
4, 4 * 10
4, 8 * 10
4IU IL-2 albumen, control group are the 0.01M phosphoric acid buffer (PB) that contains 5% glucose.IL-2 gene therapy group: 8 μ g pcDNA3/8 μ g lipofectamine (control group, injection in 24 hours in advance), 8 μ g pcDNA3-IL-2/8 μ g lipofectamine (gene therapy group, injection in 24 hours in advance).The injection cumulative volume is 10 μ l.Injected back 5 minutes, each organizes mouse peritoneal injection naloxone 4mg.kg
-1Excite Withrawal symptom, observe mouse occurs in the latent period, 15 minutes that mouse begins to jump number of skips and the body weight change of mouse in 30 minutes;
(6) IL-2 albumen suppresses the foundation of rat morphine abstinence syndrome symptom testing method
With the morphine-addicted rats model that incremental dose method is set up, give morphine after 3 hours at last, the rat of habituation is divided into 4 groups at random, every group of 5-11 only, (subarachnoid space) injects 2 * 10 respectively in the insertion catheter sheath between the 5th and the 6th lumbar vertebrae
4, 4 * 10
4, 1.4 * 10
5IU IL-2 albumen, control group are the PB that contains 5% glucose, and the injection cumulative volume is 30 μ l.Injected back 5 minutes, each organizes rats by intraperitoneal injection naloxone 4mg.kg
-1Excite Withrawal symptom, observe the various Withrawal symptoms of rat, as the wet shake of dog sample, abnormal posture, excitation, grit one's teeth, diarrhoea, hydrostomia, lose weight, and calculate Withrawal symptom general comment score value;
(7) foundation of adenovirus vector-mediated IL-2 gene inhibition mouse morphine abstinence syndrome symptom testing method
Rat inserts in the catheter sheath (subarachnoid space) and injects the PBS that contains 5% sucrose, 1 * 10 respectively between the 5th and the 6th lumbar vertebrae
7Pfu adenovirus 5 types (Ad5), 1 * 10
7PfuAd5-IL-2.The injection cumulative volume is 10 μ l.One week of injection back is measured abdominal injection naloxone 4mg.kg
-1The Withrawal symptom that excites is observed mouse occurs in the latent period, 15 minutes that mouse begins to jump number of skips and the body weight change of mouse in 30 minutes;
(8) habituation test
A. the perpendicular tail test of mouse: mouse is divided into six groups at random, and 10 every group, difference abdominal injection morphine 20mg.kg
-1(positive control), abdominal injection contain the PB (negative control) of 5% glucose, abdominal injection IL-2 albumen 1 * 10
5IU or 1 * 10
6IU, and subarachnoid injection IL-2 albumen 1 * 10
4IU or 1 * 10
5IU.Observing after the administration in 2 hours mouse has or not and S shape straub tail reaction occurs;
B. mouse jump reaction test: mouse is divided into three groups at random, every group 10, subcutaneous injection contains the PB (negative control group) or the morphine (positive controls) of 5% glucose respectively, abdominal injection IL-2 albumen, 5 times (9:00,10:00,11:00,13:00,15:00) of injection in first day, 2 times (9:00,11:00) of injection in second day.Morphine group mouse initial dose is 2.5mg.kg
-1, after this by 5,10,20,30,40,50mg.kg
-1Dosage escalation; IL-2 protein groups dosage is 1 * 10
4, 2 * 10
4, 4 * 10
4, 8 * 10
4, 1.6 * 10
5, 3.2 * 10
5And6.4 * 10
5IU.After last administration 2 hours, abdominal injection naloxone 10mg.kg
-1, observe mouse jump reaction times in 10 minutes;
(9) statistical method
Adopt one-way analysis of variance.
Method result of study of the present invention:
(1) subarachnoid injection IL-2 albumen suppresses mouse morphine abstinence syndrome symptom
Subarachnoid injection IL-2 albumen (1 * 10
4IU) can obviously prolong the latent period (p＜0.01) that mouse begins to jump, and obviously suppress the number of skips (p＜0.01) that mouse occurs, its effect is dose-dependently; IL-2 albumen (2 * 10
4IU) can obviously suppress lose weight (p＜0.05) (Fig. 1, A, B, C) of mouse.
(2) subarachnoid injection IL-2 gene (pcDNA3-IL-2) suppresses mouse morphine abstinence syndrome symptom
8 μ gpcDNA3-IL-2/8 μ glipofectamine can obviously suppress the body weight change (p＜0.05) of mouse, and can prolong the latent period (p＜0.01) that mouse begins to jump and suppress the number of skips (p＜0.01) (Fig. 1, A, B, C) that mouse occurs.
(3) subarachnoid injection IL-2 albumen suppresses rat morphine abstinence syndrome symptom
Subarachnoid injection IL-2 albumen can obviously suppress the total score value of Withrawal symptom (p＜0.05) of rat, comprises abnormal posture, excitation, diarrhoea, hydrostomia, loses weight; Wet dog sample shake, the score value of gritting one's teeth there are the tendency of minimizing, but no statistical significance.The long and shows that IL-2 albumen also can obviously suppress the most morphine abstinence syndrome symptom of rat.
(4) IL-2 albumen does not have habituation
A. the perpendicular tail test of mouse: S shape straub tail reaction all appears in morphine group mouse, and excitement is run, and IL-2 protein groups mouse does not have straub tail reaction, and is movable normal.
B. mouse jump reaction test: IL-2 protein groups (0.9 ± 0.5) is more close with control group (0.4 ± 0.3), with morphine group (14.1 ± 1.6) difference (p＜0.01) of highly significant is arranged more then.
Table 1. subarachnoid injection IL-2 albumen is to the influence of rat morphine abstinence syndrome symptom
After forming morphine dependence rat model, (subarachnoid space) injects 2 * 10 respectively in the insertion catheter sheath between the 5th and the 6th lumbar vertebrae
4, 4 * 10
4, 1.4 * 10
5IU IL-2 albumen, control group (vehicle) is for containing the PB of 5% glucose, and the injection cumulative volume is 30 μ l.Injected back 5 minutes, each organizes rats by intraperitoneal injection naloxone 4mg.kg
-1Excite Withrawal symptom, observe the various Withrawal symptoms of rat, as the wet shake of dog sample, abnormal posture, excitation, grit one's teeth, diarrhoea, hydrostomia, lose weight, and calculate Withrawal symptom general comment score value.Statistical significance is decided to be
*P＜0.05 (comparing) with vehicle.
Table 1
IL-2 dosage 2.0 * 10
4IU 4.0 * 10
4IU 1.4 * 10
5IU vehicle
Number of animals 555 11
Mobility disease score value
Wet dog sample shake 1.60 ± 0.75 0.80 ± 0.49 0 ± 0 1.27 ± 0.49
Abnormal posture 6.40 ± 1.60 6.80 ± 0.49 5.6 ± 0.75
*8.00 ± 0
Hydrostomia 1.20 ± 0.49 0 ± 0
*0.4 ± 0.4
*1.82 ± 0.12
Grit one's teeth 0.20 ± 0.20 0.10 ± 0.10 0.0 ± 0 0.27 ± 0.10
Non-mobility disease score value
Diarrhoea 5.60 ± 0.98 3.20 ± 1.50
*2.4 ± 1.6
*7.27 ± 0.49
Excitation 1.60 ± 1.60 0.8 ± 0.49
*0.4 ± 0.4
*3.54 ± 0.68
Lose weight 10.00 ± 1.58 6.00 ± 1.00
*7.00 ± 1.22
*11.82 ± 1.02
General comment score value 26.60 ± 3.01
*17.70 ± 1.74
*15.8 ± 3.43
*33.95 ± 1.06
After 7 IL-2 albumen of table 2. injected in mice (abdominal cavity) or the morphine (subcutaneous), abdominal injection naloxone 4mg.kg
-1The mouse jump that excites
Mouse subcutaneous injection respectively contains the PB (negative control group) or the morphine (positive controls) of 5% glucose, abdominal injection IL-2 albumen, 5 times (9:00,10:00,11:00,13:00,15:00) of injection in first day, 2 times (9:00,11:00) of injection in second day.Morphine group mouse initial dose is 2.5mg.kg
-1, after this by 5,10,20,30,40,50mg.kg
-1Dosage escalation; IL-2 protein groups dosage is 1 * 10
4, 2 * 10
4, 4 * 10
4, 8 * 10
4, 1.6 * 10
5, 3.2 * 10
5And 6.4 * 10
5IU.After last administration 2 hours, abdominal injection naloxone 10mg.kg
-1, observe mouse jump reaction times in 10 minutes.Statistical significance is decided to be
*P＜0.05 (comparing) with the morphine group.
Table 2
Medicine and route of administration number of skips (mouse/sum of jump)
The PB (subcutaneous injection) 0.4 ± 0.3 that contains 5% glucose
*(2/10)
Morphine (subcutaneous injection) 14.1 ± 1.6 (10/10)
IL-2 albumen (abdominal injection) 0.9 ± 0.5
*(3/10)
Description of drawings:
The influence of Fig. 1 (A, B, C) subarachnoid injection IL-2 albumen and pcDNA3-IL-2 gene pairs mouse morphine abstinence syndrome symptom
After forming the morphine-dependent mice model, (subarachnoid space) injected respectively between the 5th and the 6th lumbar vertebrae: 5 * 10
3, 1 * 10
4, 2 * 10
4, 4 * 10
4, 8 * 10
4IU IL-2 albumen, control group (vehicle) is for containing the PB of 5% glucose, n=9-18; The gene therapy group is 8 μ g pcDNA3-IL-2/8 μ g lipofectamine (injections in 24 hours in advance), and its control group is 8 μ g pcDNA3/8 μ g lipofectamine (injections in 24 hours in advance), n=10.The injection cumulative volume is 10 μ l.Injected back 5 minutes, each organizes mouse peritoneal injection naloxone 4mg.kg
-1Excite Withrawal symptom, statistics is respectively organized latent period (second) that mouse begins to jump (Figure 1A) and the number of skips (Figure 1B) of mouse appearance in 15 minutes and mouse body weight change (gram) (Fig. 1 C) in 30 minutes respectively, X-coordinate is the IL-2 concentration of subarachnoid injection among the figure, ordinate zou be respectively latent period (second) (Figure 1A), number of skips (Figure 1B) and body weight change (gram) (Fig. 1 C), statistical significance is decided to be
*P＜0.05,
*P＜0.01 (comparing) with vehicle;
#P＜0.05,
##P＜0.01 (comparing) with 8 μ g pcDNA3/8 μ g lipofectamine.
Annotate: 1. control group (vehicle)
2.5 * 10
3IU IL-2 albumen
3.1 * 10
4IU IL-2 albumen
4.2 * 10
4IU IL-2 albumen
5.4 * 10
4IU IL-2 albumen
6.8 * 10
4IU IL-2 albumen
7.8μg?pcDNA3-IL-2/8μg?lipofectamine
8.8μg?pcDNA3/8μg?lipofectamine
Show by test method results of the present invention: subarachnoid injection IL-2 albumen tool Preferably drug treatment function is arranged, and its effect is dose dependent. Be characterized in that itself does not have habituation, And can strengthen simultaneously the immunologic function of body, this drug addict to hypoimmunity has very much Benefit, habituation can not strengthen immunologic function again, is that present any methods for the treatment of can't be accomplished . The pcDNA3-IL-2 gene also has certain drug treatment function, and its effect is than high dose IL-2 Albumen is poor, may be because the instantaneous secretory volume of IL-2 albumen is lower. But then, by Expressed IL-2 albumen sustainable 6 days (than half of the IL-2 albumen of injecting in pcDNA3-IL-2 The phase of declining prolongs about 300 times), be very convenient, economical to whole withdrawal. By To the further optimization of pcDNA3-IL-2 gene importing condition, its drug abstinence is expected better, Be more suitable for practical application.
Embodiment:
(1) structure of eukaryon expression plasmid pcDNA3-IL-2
Human IL-2's gene is cut the human IL-2 cDNA (462bp) that the total length that obtains EcoR I and Xho I joint contains signal peptide through EcoR I and Xho I enzyme and is cloned into the pcDNA3 carrier of cutting through same enzyme (Invitrogen).The IL-2 gene is expressed under the control of CMV promotor, and the plasmid of structure is transformed into the e. coli jm109 amplification, and alkaline lysis prepares plasmid, the polyethylene glycol precipitation purifying.Determine plasmid concentration by the photoabsorption of measuring 260nm.Plasmid is diluted in the phosphoric acid buffer (PB) that contains 5% glucose during injection.
(2) structure of recombinant adenovirus Ad5-IL-2
Human IL-2's gene is cut the human IL-2 cDNA (462bp) that the total length that obtains EcoR I and Xho I joint contains signal peptide through EcoR I and Xho I enzyme and is cloned into the pCA13 carrier of cutting through same enzyme (Microbix).Obtain pCA13-IL-2, this moment, the IL-2 gene was expressed under the control of CMV promotor, and pCA13-IL-2 and adenoviral gene group plasmid pBHG10 (Microbix) cotransfection 293 cells carry out homologous recombination, the screening recombinant adenovirus.The amplification purification adenovirus, viral dilution is in the PBS that contains 5% sucrose during injection.
(3) foundation of morphine-dependent mice model
Form morphine-dependent mice model (this group mouse is a morphine dependence group) with incremental dose method.Morphine-dependent mice abdominal injection naloxone 4mg.kg
-1Can excite Withrawal symptom, this group mouse is the morphine abstinence syndrome group.
(4) morphine relies on the foundation of rat model
Form morphine with incremental dose method and rely on rat model (this group rat is a morphine dependence group).Morphine relies on rats by intraperitoneal injection naloxone 4mg.kg
-1Can excite Withrawal symptom, this group rat is the morphine abstinence syndrome group.
(5) foundation of the plasmid-mediated IL-2 gene inhibition of IL-2 albumen and pcDNA3 mouse morphine abstinence syndrome symptom testing method
With the morphine addiction mouse model that incremental dose method is set up, give morphine after 3 hours at last,
The mouse of habituation is divided into 8 groups at random, 10 every group.The protein for treatment group: (subarachnoid space) injects 5 * 10 respectively between the 5th and the 6th lumbar vertebrae
3, 1 * 10
4, 2 * 10
4, 4 * 10
4, 8 * 10
4IU IL-2 albumen, control group are the 0.01M phosphoric acid buffer (PB) that contains 5% glucose.IL-2 gene therapy group: 8 μ g pcDNA3/8 μ g lipofectamine (control group, injection in 24 hours in advance), 8 μ gpcDNA3-IL-2/8 μ g lipofectamine (gene therapy group, injection in 24 hours in advance).The injection cumulative volume is 10 μ l.Injected back 5 minutes, each organizes mouse peritoneal injection naloxone 4mg.kg
-1Excite Withrawal symptom, observe mouse occurs in the latent period, 15 minutes that mouse begins to jump number of skips and the body weight change of mouse in 30 minutes.
(6) IL-2 albumen suppresses the foundation of rat morphine abstinence syndrome symptom testing method
With the morphine-addicted rats model that incremental dose method is set up, give morphine after 3 hours at last, the rat of habituation is divided into 4 groups at random, every group of 5-11 only, (subarachnoid space) injects 2 * 10 respectively in the insertion catheter sheath between the 5th and the 6th lumbar vertebrae
4, 4 * 10
4, 1.4 * 10
5IU IL-2 albumen, control group are the PB that contains 5% glucose, and the injection cumulative volume is 30 μ l.Injected back 5 minutes, each organizes rats by intraperitoneal injection naloxone 4mg.kg
-1Excite Withrawal symptom, observe the various Withrawal symptoms of rat, as the wet shake of dog sample, abnormal posture, excitation, grit one's teeth, diarrhoea, hydrostomia, lose weight, and calculate Withrawal symptom general comment score value.
(7) foundation of adenovirus vector-mediated IL-2 gene inhibition mouse morphine abstinence syndrome symptom testing method
Rat inserts in the catheter sheath (subarachnoid space) and injects the PBS that contains 5% sucrose, 1 * 10 respectively between the 5th and the 6th lumbar vertebrae
7Pfu adenovirus 5 types (Ad5), 1 * 10
7PfuAd5-IL-2.The injection cumulative volume is one week of 10 μ l. injection back to measure abdominal injection naloxone 4mg.kg
-1The Withrawal symptom that excites is observed mouse occurs in the latent period, 15 minutes that mouse begins to jump number of skips and the body weight change of mouse in 30 minutes.
(8) habituation test
A. the perpendicular tail test of mouse: mouse is divided into six groups at random, and 10 every group, difference abdominal injection morphine 20mg.kg
-1(positive control), abdominal injection contain the PB (negative control) of 5% glucose, abdominal injection IL-2 albumen 1 * 10
5IU or 1 * 10
6IU, and subarachnoid injection IL-2 albumen 1 * 10
4IU or 1 * 10
5IU.Observing after the administration in 2 hours mouse has or not and S shape straub tail reaction occurs.
B. mouse jump reaction test: mouse is divided into three groups at random, every group 10, subcutaneous injection contains the PB (negative control group) or the morphine (positive controls) of 5% glucose respectively, abdominal injection IL-2 albumen, 5 times (9:00,10:00,11:00,13:00,15:00) of injection in first day, 2 times (9:00,11:00) of injection in second day.Morphine group mouse initial dose is 2.5mg.kg
-1, after this by 5,10,20,30,40,50mg.kg
-1Dosage escalation; IL-2 protein groups dosage is 1 * 10
4, 2 * 10
4, 4 * 10
4, 8 * 10
4, 1.6 * 10
5, 3.2 * 10
5And6.4 * 10
5IU.After last administration 2 hours, abdominal injection naloxone 10mg.kg
-1, observe mouse jump reaction times in 10 minutes.
(9) statistical method
Adopt one-way analysis of variance.
Claims (4)
1, interleukin II IL-2 and gene thereof the testing method in drug rehabilitation is used is characterized in that this method comprises the following steps:
(1) structure of eukaryon expression plasmid pcDNA3-IL-2
Human IL-2's gene is cut the human IL-2 cDNA 462bp that the total length that obtains EcoR I and Xho I joint contains signal peptide through EcoR I and Xho I enzyme and is cloned into the pcDNA3 carrier Invitrogen that cuts through same enzyme, the IL-2 gene is expressed under the control of CMV promotor, the plasmid that makes up is transformed into the e. coli jm109 amplification, alkaline lysis prepares plasmid, the polyethylene glycol precipitation purifying, determine plasmid concentration by the photoabsorption of measuring 260nm, plasmid is diluted in the phosphoric acid buffer that contains 5% glucose during injection;
(2) structure of recombinant adenovirus Ad5-IL-2
Human IL-2's gene is cut the human IL-2 cDNA 462bp that the total length that obtains EcoR I and Xho I joint contains signal peptide through EcoR I and Xho I enzyme and is cloned into the pCA13 carrier Microbix that cuts through same enzyme, obtain pCA13-IL-2, this moment, the IL-2 gene was expressed under the control of CMV promotor, pCA13-IL-2 and adenoviral gene group plasmid pBHG10 Microbix cotransfection 293 cells, carry out homologous recombination, the screening recombinant adenovirus, the amplification purification adenovirus, viral dilution is in the PBS that contains 5% sucrose during injection;
(3) foundation of morphine-dependent mice model
Form the morphine-dependent mice model with incremental dose method, this group mouse is a morphine dependence group, morphine-dependent mice abdominal injection naloxone 4mg.kg
-1Can excite Withrawal symptom, this group mouse is the morphine abstinence syndrome group;
(4) morphine relies on the foundation of rat model
Form morphine with incremental dose method and rely on rat model, this group rat is a morphine dependence group, and morphine relies on rats by intraperitoneal injection naloxone 4mg.kg
-1Can excite Withrawal symptom, this group rat is the morphine abstinence syndrome group;
(5) foundation of the plasmid-mediated IL-2 gene inhibition of IL-2 albumen and pcDNA3 mouse morphine abstinence syndrome symptom testing method
With the morphine addiction mouse model that incremental dose method is set up, give morphine after 3 hours at last, the mouse of habituation is divided into 8 groups at random, 10 every group, the protein for treatment group: between the 5th and the 6th lumbar vertebrae, subarachnoid space injects 5 * 10 respectively
3, 1 * 10
4, 2 * 10
4, 4 * 10
4, 8 * 10
4IU IL-2 albumen, control group is the 0.01M phosphoric acid buffer that contains 5% glucose, IL-2 gene therapy group: 8 μ g pcDNA3/8 μ g lipofectamine, control group, injection in 24 hours in advance, 8 μ g pcDNA3-IL-2/8 μ g lipofectamine, the gene therapy group, injection in 24 hours in advance, the injection cumulative volume is 10 μ l, injected back 5 minutes, each organizes mouse peritoneal injection naloxone 4mg.kg
-1Excite Withrawal symptom, observe mouse occurs in the latent period, 15 minutes that mouse begins to jump number of skips and the body weight change of mouse in 30 minutes;
(6) IL-2 albumen suppresses the foundation of rat morphine abstinence syndrome symptom testing method
With the morphine-addicted rats model that incremental dose method is set up, give morphine after 3 hours at last, the rat of habituation is divided into 4 groups at random, every group of 5-11 only, in the insertion catheter sheath, subarachnoid space injects 2 * 10 respectively between the 5th and the 6th lumbar vertebrae
4, 4 * 10
4, 1.4 * 10
5IU IL-2 albumen, control group are the PB that contains 5% glucose, and the injection cumulative volume is 30 μ l, injects back 5 minutes, and each organizes rats by intraperitoneal injection naloxone 4mg.kg
-1Excite Withrawal symptom, observe the various Withrawal symptoms of rat, as the wet shake of dog sample, abnormal posture, excitation, grit one's teeth, diarrhoea, hydrostomia, lose weight, and calculate Withrawal symptom general comment score value;
(7) foundation of adenovirus vector-mediated IL-2 gene inhibition mouse morphine abstinence syndrome symptom testing method
Rat inserts between the 5th and the 6th lumbar vertebrae in the catheter sheath, subarachnoid space, and injection contains the PBS of 5% sucrose, 1 * 10 respectively
7Pfu adenovirus 5 type Ad5,1 * 10
7PfuAd5-IL-2.The injection cumulative volume is 10 μ l.One week of injection back is measured abdominal injection naloxone 4mg.kg
-1The Withrawal symptom that excites is observed mouse occurs in the latent period, 15 minutes that mouse begins to jump number of skips and the body weight change of mouse in 30 minutes;
(8) habituation test
A. the perpendicular tail test of mouse: mouse is divided into six groups at random, and 10 every group, difference abdominal injection morphine 20mg.kg
-1Positive control, abdominal injection contain the PB negative control of 5% glucose, abdominal injection IL-2 albumen 1 * 10
5IU or 1 * 10
6IU, and subarachnoid injection IL-2 albumen 1 * 10
4IU or 1 * 10
5IU observes after the administration in 2 hours mouse and has or not and S shape straub tail reaction occurs;
B. mouse jump reaction test: mouse is divided into three groups at random, every group 10, subcutaneous injection contains the PB negative control group or the morphine positive controls of 5% glucose respectively, abdominal injection IL-2 albumen, injection in first day 5 times, 9:00,10:00,11:00,13:00,15:00, injection in second day 2 9:00,11:00, morphine group mouse initial dose is 2.5mg.kg
-1, after this by 5,10,20,30,40,50mg.kg
-1Dosage escalation; IL-2 protein groups dosage is 1 * 10
4, 2 * 10
4, 4 * 10
4, 8 * 10
4, 1.6 * 10
5, 3.2 * 10
5And 6.4 * 10
5IU, after last administration 2 hours, abdominal injection naloxone 10mg.kg
-1, observe mouse jump reaction times in 10 minutes;
(9) statistical method
Adopt one-way analysis of variance.
2, interleukin II according to claim 1 and gene thereof the testing method in drug rehabilitation is used is characterized in that the route of administration that wherein adopts is a subarachnoid administration.
3, interleukin II according to claim 1 and gene thereof the testing method in drug rehabilitation is used is characterized in that the IL-2 protein that IL-2 and pcDNA3-IL-2 or Ad5-IL-2 express at subarachnoid space.
4, interleukin II according to claim 1 and gene thereof the testing method in drug rehabilitation is used is characterized in that wherein said habituation type is the opioid habituation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02155058 CN1238522C (en) | 2002-12-20 | 2002-12-20 | Interleukin-2 and tes method of its gene in drug-stopping application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02155058 CN1238522C (en) | 2002-12-20 | 2002-12-20 | Interleukin-2 and tes method of its gene in drug-stopping application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1508265A true CN1508265A (en) | 2004-06-30 |
| CN1238522C CN1238522C (en) | 2006-01-25 |
Family
ID=34235673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02155058 Expired - Fee Related CN1238522C (en) | 2002-12-20 | 2002-12-20 | Interleukin-2 and tes method of its gene in drug-stopping application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1238522C (en) |
-
2002
- 2002-12-20 CN CN 02155058 patent/CN1238522C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1238522C (en) | 2006-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1268640C (en) | Glucagon-like peptide-2 analogs | |
| ES2825076T3 (en) | Pharmaceutical compositions | |
| CN1413110A (en) | Pharmaceutical composition | |
| CN103167878A (en) | Treating diabetes melitus using insulin injections administered with varying injection intervals | |
| PT639079E (en) | COMPOSITION FOR TREATMENT OF DISEASES MEDIATED BY INTERLEUQUIN-1 AND TUMOR NECROSIS FACTOR | |
| CN1293922C (en) | Gene therapy for cardiomyopathy | |
| CN107213149B (en) | Application of artemisinin derivatives in preparation of drugs for treating or assisting in treating autoimmune thyroid diseases | |
| JP2020037562A (en) | Methods for treatment of inflammatory joint disease | |
| JP2022060514A (en) | Treatment of neuropathy with dna construct expressing hgf isoforms with reduced interference from gabapentinoids | |
| CN1195728C (en) | Novel compounds to treat diabetes and associated conditions | |
| CN1149822A (en) | Therapeutical homeopathic dilutions of growth factors and methods of their use | |
| CN1238522C (en) | Interleukin-2 and tes method of its gene in drug-stopping application | |
| CN1735427A (en) | Pain relief agents | |
| CN104853778A (en) | Therapeutic agent for amyotrophic lateral sclerosis | |
| CN114887063B (en) | Application of Pacsin1 in inhibition of remifentanil-induced hyperalgesia | |
| ZA200700524B (en) | Methods of healing wounds by administering human IL-18 | |
| Wang et al. | Experimental study of TNF‑α receptor gene transfection by ultrasound‑targeted microbubble destruction to treat collagen‑induced arthritis in rats in vivo | |
| CN101035805A (en) | Deglycosylated and desialidated long pentraxin PTX3 | |
| CN1090491A (en) | Prevent and treat pyemic method | |
| Stellar et al. | Neonatal dopamine depletions spare lateral hypothalamic stimulation reward in adult rats | |
| US20130129670A1 (en) | Macrophage activating factor for use in the treatment of chronic fatigue syndrome (cfs) and cfs-related diseases and disorders | |
| CN1173819A (en) | Methods of inhibiting effects of IL_6 | |
| CN1193104C (en) | Method for testing application of interleukin-2 gene in chronic pain | |
| AU6169894A (en) | Methods for treating amyotrophic lateral sclerosis with cntf | |
| CN108018311A (en) | Cachexia is treated by gene editing special target musculature MSTN |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060125 Termination date: 20161220 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |